Literature DB >> 31941467

Prognostic factors of patients with Gliomas - an analysis on 335 patients with Glioblastoma and other forms of Gliomas.

Jianfeng Liang1, Xiaomin Lv2, Changyu Lu1, Xun Ye1,3, Xiaolin Chen1,3, Jia Fu1, Chenghua Luo4, Yuanli Zhao5,6.   

Abstract

BACKGROUND: The prognosis of glioma is poor, despite recent advances in diagnosis and treatment of the disease. It is important to investigate the clinical characteristics and prognostic factors of glioma so as to provide basis for treatment and management of patients.
METHOD: A total of 335 patients with glioma were included in this study. These patients were admitted to the medical center between November 2015 and December 2018. The clinical data, including demographic data, tumor characteristics, treatment strategy, expression pattern of tumor markers, and survival data, were retrospectively reviewed. Survival data were analyzed using Kaplan-Meier curves with log-rank test, while multivariate analysis Cox regression model was used to investigate risk factors for mortality.
RESULTS: In this patient cohort, glioblastoma (40%), diffuse glioma (14.6%) and oligodendroglioma (9.6%) were the most common pathological types. The expression of Ki-67 was associated with several clinicopathological parameters (e.g. tumor type, grade, and number of lesions). In addition, Ki-67 correlated with the mortality within the first year of the post-treatment follow-up (P <  0.001). Kaplan-Maier analysis revealed that older patients (≥ 45 years) displayed worse prognosis than those aged under 45 years (P = 0.038). Dismal prognosis was also associated with clinical parameters, including high tumor grade, multiple lesions, and Karnofsky performance score (KPS). Multivariate analysis showed that low KPS (< 85) increased the risk of mortality by 2.3 folds with a 95% CI of 1.141 to 4.776 (P = 0.020). Low tumor grade (grade 1-2) oppositely reduced the mortality risk by 0.22 folds (95% CI, 0.065 to 0.763, P = 0.0168).
CONCLUSION: KPS and tumor grade were independent prognostic factors in patients with gliomas.

Entities:  

Keywords:  Clinical characteristics; Glioblastoma; Gliomas; Prognostic factors; Survival

Year:  2020        PMID: 31941467     DOI: 10.1186/s12885-019-6511-6

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  26 in total

1.  Assessing mobility in primary brain tumor patients: A descriptive feasibility study using two established mobility tests.

Authors:  James L Rogers; Julianie De La Cruz Minyety; Elizabeth Vera; Alvina A Acquaye; Samuel S Payén; Jeffrey S Weinberg; Terri S Armstrong; Shiao-Pei S Weathers
Journal:  Neurooncol Pract       Date:  2022-02-17

2.  Hypofractionated radiation therapy with temozolomide versus standard chemoradiation in patients with glioblastoma multiforme (GBM): A prospective, single institution experience.

Authors:  Amal Rayan; Samya Abdel-Kareem; Huda Hasan; Asmaa M Zahran; Doaa A Gamal
Journal:  Rep Pract Oncol Radiother       Date:  2020-08-25

3.  Tumor cell and immune cell profiles in primary human glioblastoma: Impact on patient outcome.

Authors:  María González-Tablas Pimenta; Álvaro Otero; Daniel Angel Arandia Guzman; Daniel Pascual-Argente; Laura Ruíz Martín; Pablo Sousa-Casasnovas; Andoni García-Martin; Juan Carlos Roa Montes de Oca; Javier Villaseñor-Ledezma; Luis Torres Carretero; Maria Almeida; Javie Ortiz; Adelaida Nieto; Alberto Orfao; María Dolores Tabernero
Journal:  Brain Pathol       Date:  2021-02-13       Impact factor: 6.508

4.  Decision making and surgical modality selection in glioblastoma patients: an international multicenter survey.

Authors:  Jasper K W Gerritsen; Marike L D Broekman; Steven De Vleeschouwer; Philippe Schucht; Christine Jungk; Sandro M Krieg; Brian V Nahed; Mitchel S Berger; Arnaud J P E Vincent
Journal:  J Neurooncol       Date:  2022-01-24       Impact factor: 4.130

5.  Survival prediction in glioblastoma on post-contrast magnetic resonance imaging using filtration based first-order texture analysis: Comparison of multiple machine learning models.

Authors:  Sarv Priya; Amit Agarwal; Caitlin Ward; Thomas Locke; Varun Monga; Girish Bathla
Journal:  Neuroradiol J       Date:  2021-02-03

6.  LncRNA ADAMTS9-AS1 knockdown suppresses cell proliferation and migration in glioma through downregulating Wnt/β-catenin signaling pathway.

Authors:  Chunhui Zhou; Hulin Zhao; Shuiwei Wang; Chao Dong; Fan Yang; Jianning Zhang
Journal:  Bosn J Basic Med Sci       Date:  2022-06-01       Impact factor: 3.759

7.  Receptor-Interacting Protein 140 Enhanced Temozolomide-Induced Cellular Apoptosis Through Regulation of E2F1 in Human Glioma Cell Lines.

Authors:  Hong-Chieh Tsai; Kuo-Chen Wei; Pin-Yuan Chen; Chiung-Yin Huang; Ko-Ting Chen; Ya-Jui Lin; Hsiao-Wei Cheng; Chun-Hao Huang; Hsiang-Tsui Wang
Journal:  Neuromolecular Med       Date:  2021-06-01       Impact factor: 3.843

Review 8.  Neuroinflammation: A Signature or a Cause of Epilepsy?

Authors:  Enrico Pracucci; Vinoshene Pillai; Didi Lamers; Riccardo Parra; Silvia Landi
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

9.  Downregulation of S100 calcium binding protein A12 inhibits the growth of glioma cells.

Authors:  Chunhe Lu; Jia Liu; Mingze Yao; Lun Li; Guangyu Li
Journal:  BMC Cancer       Date:  2020-03-30       Impact factor: 4.430

10.  Three-Dimensional Nuclear Telomere Profiling as a Biomarker for Recurrence in Oligodendrogliomas: A Pilot Study.

Authors:  Macoura Gadji; Shubha Mathur; Brigitte Bélanger; Jaganmohan Reddy Jangamreddy; Josée Lamoureux; Ana Maria Crous Tsanaclis; David Fortin; Régen Drouin; Sabine Mai
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.